Skip to main content

Table 1 Patients, investigations, follow-up and treatments characteristics

From: Multidimensional analyses to assess the relations between treatment choices by physicians and patients’ characteristics: the example of COPD

N = 2494 Mean ± SD or%
Age (years) 67.0 ± 10.6
Male (%) 78%
Body mass index (kg/m2) 25.84 ± 5.17
Smokers / ex-smokers 25.6% / 62.4%
Chronic bronchitis without airflow obstruction / COPD 23.7% / 76.3%
(GOLD stage): 1 / 2 / 3 / 4 2.9% / 29.7% / 26.1% / 17.6% /
FEV1 (L/sec) 53.1 ± 19.6
Duration of chronic bronchitis / COPD (years) 8.0 ± 7.8
Chronic cough / sputum production 70.5% / 72.2%
Chronic cough with sputum production by GOLD stage in COPD patients: GOLD 1/2/3/4 62.0% / 71.9% / 72.4% / 76.4%
Modified Medical Research Council dyspnea grade: 1 / 2 / 3 / 4 / 5 14.2% / 30.3% / 30.5% / 16.2% / 6.1%
At least one exacerbation during the last 12 months 86.3%
Number of exacerbations per year
-Mild / moderate (oral corticosteroids or antibiotics) 1.4 ± 2.3 / 1.6 ± 1.7
-Severe (hospitalization) / very severe (intensive care unit) 0.3 ± 0.8 / 0.0 ± 0.2
Comorbidities
-CHD / CHF / RVF 14.9% / 6.5% / 7.2%
-Asthma / bronchiectasis / sleep apnea syndrome 11.9% / 6.3% / 8.6%
-Depression 7.9%
Investigations and follow-up during the past 12 months
-Arterial blood gases / EKG 70.0% / 68.8%
-CT-scan / echocardiography 61.6% / 50.6%
-Sleep oximetry / polysomnography 23.2% / 15.4%
-6MWT 27.9%
 Visits to respiratory physicians / GPs 2.6 ± 1.7 / 6.7 ± 4.1
Treatments
-ICS / Fixed ICS + LABA combinations 22.8% / 51.5%
-SABA / SABA + SAMA 34.9% / 29.9%
-LABA / LAMA 26.6% / 17.0%
-Theophylline / oral corticosteroids 8.3% / 4.5%
-LTOT / LTNIV 16.6% / 4.8%
-Influenza / pneumococcal vaccines 81.2% / 58.2%
-Rehabilitation during the last 2 years 26.9%
  1. CHD: coronary heart disease; CHF: congestive heart failure; RVF: right ventricular failure; EKG: electrocardiogram; 6MWT: 6-minutes walk test; GP: general practitioner; ICS: inhaled corticosteroids; SABA/LABA: short/long-acting beta-agonists; SAMA/LAMA: short/long-acting anticholinergics; LTOT/LTNIV: long-term oxygen therapy / non-invasive ventilation.